ANGO: financial statements from SEC — TradeAlmanac

ANGO

AngioDynamics, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	May 31, 2025	May 31, 2024
Revenue	292m	304m
Cost of revenue	135m	149m
Gross profit	158m	155m
Research and development	26m	32m
Selling, general and administrative	42m	41m
Operating expenses	198m	402m
Operating income	−40m	−192m
Interest expense	—	−2m
Pre-tax income	−34m	−192m
Income tax	−39,000	−7m
Net income	−34m	−184m
Earnings per share	−0.83	−4.59
Earnings per share, diluted	−0.83	−4.59
Weighted average shares	41m	40m
Weighted average shares, diluted	41m	40m

Balance sheet

Metric	Feb 28, 2026	Nov 30, 2025	Aug 31, 2025	May 31, 2025	Feb 28, 2025	Nov 30, 2024	Aug 31, 2024	May 31, 2024
Cash and equivalents	38m	42m	39m	56m	45m	54m	55m	76m
Receivables	46m	44m	43m

Cash flow

Metric	May 31, 2025	May 31, 2024
Operating cash flow	−10m	−28m
Depreciation and amortisation	26m	28m
Share-based compensation	10m	11m
Capital expenditure	4m	3m
Investing cash flow	−10m	124m
Share buybacks	2m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)